Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.51 |
| ▸ | HTR1A | P08908 | 9/20 | 0.49 |
| ▸ | HTR2A | P28223 | 8/20 | 0.49 |
| ▸ | DRD3 | P35462 | 8/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339859 | 0.98 | DRD2 (0.51) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL14339857 | 0.94 | DRD2 (0.53) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5265394 | 0.83 | DRD2 (0.53) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5263145 | 0.83 | DRD2 (0.49) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5473542 | 0.81 | DRD2 (0.46) | DRD2HTR1AHTR2AADRA1DADRA1A | |
| SCHEMBL5266891 | 0.81 | DRD2 (0.43) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5261982 | 0.81 | DRD2 (0.53) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5266898 | 0.81 | DRD2 (0.49) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL14339851 | 0.81 | DRD2 (0.76) | DRD2HTR1AHTR2ADRD3DRD4 | |
| SCHEMBL5461977 | 0.79 | DRD2 (0.47) | DRD2HTR1AHTR2AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | claimed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | claimed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | DRD2 64/4885HTR1A 3/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.